<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512430</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 20/01_Neo-DIANA</org_study_id>
    <secondary_id>2020-000642-33</secondary_id>
    <nct_id>NCT04512430</nct_id>
  </id_info>
  <brief_title>Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients</brief_title>
  <official_title>A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación GECP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación GECP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomised, phase II, multi-centre clinical trial&#xD;
&#xD;
      26 patients will be enrolled in this trial to evaluate the major pathologic response in&#xD;
      patients with neoadjuvant treatment with Carboplatin Pemetrexed Bevacizumab plus Atezolizumab&#xD;
      in patients with non-small cell lung carcinoma locally advanced mutated in EGFR&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomised, phase II, multi-centre clinical trial. Patients&#xD;
      enrolled will receive Atezolizumab 1200mg + Bevacizumab 15mg/Kg + Carboplatin AUC6 +&#xD;
      Pemetrexed 500mg/m2 for 3 cycles every 21 days (+/- 3 days) as neoadjuvant treatment followed&#xD;
      by surgery and 6 months of adjuvant treatment with Atezolizumab 1200 mg Q4W (+/- 3 days).&#xD;
&#xD;
      The primary objective is to evaluate the major pathologic response defined as 10 percent or&#xD;
      fewer viable cancer cells detectable in the resected tumor and in lymph nodes in stage IIIA&#xD;
      EGFR mutated patients treated in neoadjuvant setting with atezolizumab- bevacizumab-&#xD;
      carboplatin and pemetrexed.&#xD;
&#xD;
      Patient accrual is expected to be completed within 2 years excluding a run-in-period of 3-6&#xD;
      months. Treatment and follow-up are expected to extend the study duration to a total of 6&#xD;
      years. Patients will be followed 3 years after adjuvant treatment. The study will end once&#xD;
      survival follow-up has concluded. This will be followed by a close out period of 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathologic response</measure>
    <time_frame>From date of end of neoadjuvant treatment until the date of last follow up, assessed up to 36 months</time_frame>
    <description>To evaluate the major pathologic response (MPR) defined as 10 percent or fewer viable cancer cells detectable in the resected tumor and in lymph nodes in stage IIIA EGFR mutated patients treated in neoadjuvant setting with atezolizumab-bevacizumab- carboplatin and pemetrexed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>To evaluate the Overall Survival (OS) rate at 1 year, 2 and 3 years</time_frame>
    <description>defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>To evaluate at 1 year of treatment</time_frame>
    <description>defined as the length of time from the date of diagnosis to the date of the first documented progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>From date of end of neoadjuvant treatment until the date of last follow up, assessed up to 36 months</time_frame>
    <description>Rate of complete response: Disappearance of all target lesions. Lymph nodes selected as target lesions must each have reduction in the short axis to &lt; 10 mm in order for the response to be considered complete. In this case, the sum of diameters may be &gt; 0.Disappearance of all non-target lesions; lymph nodes selected as non-target lesions must be non-pathological in size (&lt; 10 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Downstaging after surgery</measure>
    <time_frame>After surgery within the 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) (each cycle is 21 days +/- 3 days)</time_frame>
    <description>To evaluate a reduction in the stage of a cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>From the subject's written consent to participate in the study through 100 days after the final administration of the drug</time_frame>
    <description>Occurrence and severity of adverse events, with severity determined by NCI CTCAE v5.0 criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor</condition>
  <arm_group>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant treatment: (Atezolizumab: 1200 mg, IV infusion+Bevacizumab: 15mg/Kg mg, IV infusion+Carboplatin: AUC6, IV infusion+Pemetrexed: 500 mg/m2, IV infusion) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery.Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.&#xD;
Surgery: Surgery must be done within the 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3).&#xD;
Adjuvant treatment: Atezolizumab: 1200 mg, IV infusion Q4W (+/- 3 days) for 6 months (6 cycles) Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+7 days) from surgery and for 6 months (6 cycles).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.&#xD;
First Infusion&#xD;
No premedication administered for atezolizumab specifically is permitted&#xD;
Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.&#xD;
Subsequent Infusions:&#xD;
If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles &gt; 2 at the discretion of the treating physician.&#xD;
If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes.</description>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.</description>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.&#xD;
Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.&#xD;
Guidelines of Carboplatin administration: According to the standard of each center</description>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.&#xD;
Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo[2,3 d]pyrimidine-based folic acid analogue.&#xD;
Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center</description>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Previously untreated patients with histologically- or cytologically- documented&#xD;
             NSCLC who present stage IIIA disease (according to 8th version of the International&#xD;
             Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). PET/CT&#xD;
             including IV contrast (CT of diagnostic quality) will be performed at baseline (28&#xD;
             days +10 before randomization).&#xD;
&#xD;
          -  2. Tumor should be considered resectable before study entry by a multidisciplinary&#xD;
             team&#xD;
&#xD;
          -  3. Sensitizing EGFR mutation (Del Exon 19 and ins Exon 21).&#xD;
&#xD;
          -  4. ECOG (Performance status) 0-1&#xD;
&#xD;
          -  5. Screening laboratory values must meet the following criteria and should be obtained&#xD;
             within 14 days prior to randomization i. Neutrophils ≥ 1500×109/L ii. Platelets ≥ 100&#xD;
             ×109/L iii. Hemoglobin &gt; 9.0 g/dL iv. Serum creatinine ≤ 1.5 x ULN or creatinine&#xD;
             clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below): a. Female&#xD;
             CrCl = (140 - age in years) x weight in kg x 0.85/ 72 x serum creatinine in mg/dL b.&#xD;
             Male CrCl = (140 - age in years) x weight in kg x 1.00/ 72 x serum creatinine in mg/dL&#xD;
             v. AST/ALT ≤ 3 x ULN vi. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert&#xD;
             Syndrome, who can have total bilirubin &lt; 3.0 mg/dL) vii. PT/APTT/INR within normal&#xD;
             limits&#xD;
&#xD;
          -  6. Measurable or evaluable disease according to RECIST v1.1.&#xD;
&#xD;
          -  7. The patients need to have a forced expiratory volume (FEV1)≥ 1.2 liters or &gt;40% p-&#xD;
             predicted value.&#xD;
&#xD;
          -  8. All patients are notified of the investigational nature of this study and signed a&#xD;
             written informed consent in accordance with institutional and national guidelines,&#xD;
             including the Declaration of Helsinki prior to any trial-related intervention.&#xD;
&#xD;
          -  9. Patients aged &gt; 18 years.&#xD;
&#xD;
          -  10. Patient capable of proper therapeutic compliance and accessible for correct&#xD;
             follow-up.&#xD;
&#xD;
          -  11. For female patients of childbearing potential, agreement (by patient and/or&#xD;
             partner) to use a highly effective form(s) of contraception that results in a low&#xD;
             failure rate (&lt; 1% per year) when used consistently and correctly, and to continue its&#xD;
             use for 5 months after the last dose of Atezolizumab and/or 6 months after the last&#xD;
             dose of Bevacizumab, whichever is later. Such methods include: combined (estrogen and&#xD;
             progestogen containing) hormonal contraception, progestogen-only hormonal&#xD;
             contraception associated with inhibition of ovulation together with another additional&#xD;
             barrier method always containing a spermicide, intrauterine device (IUD): intrauterine&#xD;
             hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on&#xD;
             the understanding that this is the only one partner during the whole study duration),&#xD;
             and sexual abstinence.&#xD;
&#xD;
          -  12. For male patients with female partners of childbearing potential, agreement (by&#xD;
             patient and/or partner) to use a highly effective form(s) of contraception that&#xD;
             results in a low failure rate [&lt; 1% per year] when used consistently and correctly,&#xD;
             and to continue its use for 6 months after the last dose of Bevacizumab. Male patients&#xD;
             should not donate sperm during this study and for at least 6 months after the last&#xD;
             dose of Bevacizumab.&#xD;
&#xD;
          -  13. Oral contraception should always be combined with an additional contraceptive&#xD;
             method because of a potential interaction with the study drugs. The same rules are&#xD;
             valid for male patients involved in this clinical study if they have a partner of&#xD;
             childbirth potential. Male patients must always use a condom.&#xD;
&#xD;
          -  14. Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea)&#xD;
             or surgically sterile must have a negative serum pregnancy test result within 14 days&#xD;
             prior to initiation of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. All patients carrying other EGFR mutations.&#xD;
&#xD;
          -  2. Patients with known anaplastic lymphoma kinase (ALK) fusion oncogene, STK11 ligand&#xD;
             alteration or ROS1 translocations.&#xD;
&#xD;
          -  3. Clinically significant comorbidities that impaired administration of platinum-based&#xD;
             chemotherapy.&#xD;
&#xD;
          -  4. Patients with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt;10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of randomization. Inhaled or topical steroids, and adrenal replacement steroid&#xD;
             doses &gt; 10 mg daily prednisone equivalent, are permitted in the absence of active&#xD;
             autoimmune disease.&#xD;
&#xD;
          -  5. Patients with a history of interstitial lung disease cannot be included if they&#xD;
             have symptomatic ILD (Grade 3-4) and/or poor lung function. In case of doubt please&#xD;
             contact trial team.&#xD;
&#xD;
          -  6. Patients with other active malignancy requiring concurrent intervention and/or&#xD;
             concurrent treatment with other investigational drugs or anti-cancer therapy.&#xD;
&#xD;
          -  7. Patients with previous malignancies (except non-melanoma skin cancers, and the&#xD;
             following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia,&#xD;
             melanoma, or breast) are excluded unless a complete remission was achieved at least 2&#xD;
             years prior to study entry AND no additional therapy is required during the study&#xD;
             period.&#xD;
&#xD;
          -  8. Any medical, mental or psychological condition which in the opinion of the&#xD;
             investigator would not permit the patient to complete the study or understand the&#xD;
             patient information.&#xD;
&#xD;
          -  9. Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or&#xD;
             hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic&#xD;
             infection.&#xD;
&#xD;
          -  10. Patients with known history of testing positive for human immunodeficiency virus&#xD;
             (HIV) or known acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          -  11. Active tuberculosis.&#xD;
&#xD;
          -  12. Severe infections within 4 weeks prior to be included in the study, including but&#xD;
             not limited to hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia.&#xD;
&#xD;
          -  13. Patients with history of allergy to study drug components excipients.&#xD;
&#xD;
          -  14. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins.&#xD;
&#xD;
          -  15. Women who are pregnant or in the period of breastfeeding.&#xD;
&#xD;
          -  16. Sexually active men and women of childbearing potential who are not willing to use&#xD;
             an effective contraceptive method during the study.&#xD;
&#xD;
          -  17.&#xD;
&#xD;
               -  Patients with active, known or suspected autoimmune disease, including but not&#xD;
                  limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
                  erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular&#xD;
                  thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis,&#xD;
                  Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or&#xD;
                  glomerulonephritis.&#xD;
&#xD;
               -  Patients with a history of autoimmune-related hypothyroidism on a stable dose of&#xD;
                  thyroid replacement hormone are eligible for this study.&#xD;
&#xD;
               -  Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin&#xD;
                  regimen are eligible for this study.&#xD;
&#xD;
               -  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
                  dermatologic manifestations only (e.g., patients with psoriatic arthritis would&#xD;
                  be excluded) are permitted provided that they meet the following conditions:&#xD;
&#xD;
                    -  Rash must cover less than 10% of body surface area (BSA).&#xD;
&#xD;
                    -  Disease is well controlled at baseline and only requiring low-potency&#xD;
                       topical steroids.&#xD;
&#xD;
                    -  No acute exacerbations of underlying condition within the previous 12 months&#xD;
                       (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate,&#xD;
                       retinoids, biologic agents, oral calcineurin inhibitors, high-potency or&#xD;
                       oral steroids).&#xD;
&#xD;
          -  18. Patients with any contraindication for bevacizumab administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta del Hierro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Pereira</last_name>
    <phone>+34934302006</phone>
    <email>epereira@gecp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Badalona, Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enric Carcereny, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enric Carcereny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Nadal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ernest Nadal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delvys Rodriguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Delvys Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Iruña</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Teijeira Teijeira, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Teijeira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario García Campelo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosario García Campelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Franco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Franco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerardo Huidobro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gerardo Huidobro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria González, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Martínez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alex Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona, Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquim Bosch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquim Bosch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Laura Ortega Granados, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Laura Ortega Granados, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Fernández, MD</last_name>
    </contact>
    <investigator>
      <last_name>Natalia Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Dómine, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Dómine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Cobo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Cobo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Marsé, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raquel Marsé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edel del Barco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edel del Barco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Bernabé, MD</last_name>
    </contact>
    <investigator>
      <last_name>Reyes Bernabé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael López, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Web page of the sponsor where users can find more information about Fundación GECP studies</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <keyword>Adjuvant treatment</keyword>
  <keyword>Antineoplastic Agents, Immunological</keyword>
  <keyword>EGFR Mutation</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

